| 其它关联资金 | | 占用方与上市 | 上市公司核算 | 2023 年期初 | 年 2023 | 月占用累 1-6 | 2023 | 年 月占 1-6 | 2023 | 年 1-6 | 月 2023 | 年 月 6 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 往来 | 资金占用方名称 | 公司的关联关 系 | 的会计科目 | 占用资金余额 | | 计发生金额（不含利 | | 用资金的利息(如 | | 偿还累计发生 | | 末占用资金 | 占用形成原因 | 占用性质 | | | | | | | | 息） | | 有) | | 金额 | | 余额 | | | | | 瑞普高科（天津）生物技术有限公司 | 子公司 | 应收账款 | 1,914.58 | | | 10.15 | | | | 190.22 | 1,734.51 销售商品 | | 经营性往来 | | | 山西福瑞沃农大生物技术工程有限公司 | 子公司 | 应收账款 | 40.00 | | | | ...

天津瑞普生物技术股份有限公司 2023年半年度募集资金存放与使用情况专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 以及 《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式（2023 年修订）》的相关规定，本公司就 2023 年半年度募集资金存放与使用情况作如 下专项报告： 一、 募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会于 2021 年 9 月 10 日下发的《关于同意天津瑞普 生物技术股份有限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2974 号）同意，公司向特定对象发行人民币普通股（A 股）63,984,674 股，发行价格 为人民币 20.88 元/股，募集资金总额为人民币 1,335,999,993.12 元，扣除各项 发行费用（不含税）人民币 13,979,522.73 元后，募集资金净额为人民币 1,322,020,470.39 元。 上述 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）董事会近日收到了 佟秋月女士提交的书面辞职报告。佟秋月女士因个人原因，申请辞去公司副总 经理的职务，佟秋月女士辞职后，将不再担任公司任何职务。 证券代码：300119 证券简称：瑞普生物 公告编号：2023-056 天津瑞普生物技术股份有限公司 关于副总经理辞职的公告 天津瑞普生物技术股份有限公司 董事会 二〇二三年八月二十六日 1 佟秋月女士担任的公司副总经理职务的原定任期为2022年9月13日至2025年 9月12日止。截至本公告披露之日，佟秋月女士持有公司股份28,500股，其中包 含股权激励限制性股票18,000股将根据公司《2022年限制性股票激励计划（草案） （修订稿）》等规定由公司回购注销。在辞去公司副总经理职务后，佟秋月女士 所持公司股份将依据《公司法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律 法规和业务规则的规定进行管理。佟秋月女士不存在应当履行而未履行的承诺事 项。 佟秋月 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-049 天津瑞普生物技术股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 天津瑞普生物技术股份有限公司（以下简称"公司"）第五届监事会第七次 会议于 2023 年 8 月 24 日在公司会议室以现场结合通讯表决方式召开。会议通知 于 2023 年 8 月 14 日以电子邮件等网络方式送达全体监事。公司应出席监事 3 人，实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生 主持。本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规 和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 经审议，监事会认为公司《2023年半年度报告全文》及《2023年半年度报 告摘要》编制及审议程序符合法律、行政法规等有关规定，报告内容真实、准 确、完整地反映了公司2023年上半年经营的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 具体内容详见公 ...

特别提示： 证券代码：300119 证券简称：瑞普生物 公告编号：2023-047 天津瑞普生物技术股份有限公司 1、本次回购注销 2022 年限制性股票激励计划已授予但尚未解除限售的限制 性股票数量合计 174.26 万股，占回购注销前公司总股本的 0.37%，涉及激励对象 204 人。 关于 2022 年限制性股票激励计划部分限制性股票 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次部分 限制性股票注销事宜已于 2023 年 8 月 24 日办理完成。 3、注销完成后，公司股份总数由 468,018,786 股减少至 466,276,186 股。 回购注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 （三）2022 年 5 月 16 日，公司 2022 年第一次临时股东大会审议通过了《关 于<公司 2022 年限制性股票激励计划(草案)>及其摘要的议案》《关于<公司 2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股东大会授 权董事会办理 2022 年限制性股票激励计划相关事宜的议案》，公司董事 ...

1、通用名称：猫鼻气管炎、杯状病毒病、泛白细胞减少症三联灭活疫苗 （RPVF0304 株+RPVF0207 株+RPVF0110 株） 2、研制单位：天津瑞普生物技术股份有限公司、天津瑞普生物技术股份有 限公司空港经济区分公司、瑞普（保定）生物药业有限公司 证券代码：300119 证券简称：瑞普生物 公告编号：2023-046 天津瑞普生物技术股份有限公司 关于猫鼻气管炎、杯状病毒病、泛白细胞减少症三联灭活疫苗 通过农业农村部应急评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》《兽药注册办法》等有关规定，经中华人民共和国农 业农村部审查，天津瑞普生物技术股份有限公司（以下简称"公司"）研制的猫 鼻气管炎、杯状病毒病、泛白细胞减少症三联灭活疫苗（RPVF0304 株+RPVF0207 株+RPVF0110 株）（以下简称"猫三联疫苗"）已通过农业农村部组织的应急评 价，具体情况如下： 一、应急评价产品基本情况 3、作用与用途：用于预防猫鼻气管炎、杯状病毒病和泛白细胞减少症。二 免后 21 日产生免疫力，免疫持续期为 12 个月。 ...

Financial Performance - The company's revenue for Q1 2023 was ¥442,780,482.14, representing a 13.30% increase compared to ¥390,806,576.59 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥80,823,461.46, up 11.93% from ¥72,205,916.82 year-on-year[4] - Total operating revenue for Q1 2023 reached ¥442,780,482.14, an increase of 13.3% compared to ¥390,806,576.59 in the same period last year[24] - The net profit for Q1 2023 was CNY 87,502,825.62, an increase of 9.4% compared to CNY 79,588,705.19 in Q1 2022[26] - The operating profit for the quarter was CNY 98,534,255.21, up from CNY 84,660,247.50 in the same period last year, reflecting a growth of 16.5%[26] - The total comprehensive income for the quarter was CNY 87,502,825.62, compared to CNY 79,588,705.19 in Q1 2022, indicating a growth of 9.4%[27] Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥29,212,171.85, a 153.56% increase from a negative cash flow of -¥54,538,255.13 in the previous year[4] - The company's cash and cash equivalents decreased by 90.36% to -¥54,701,596.71, influenced by comprehensive cash flow impacts from operating, investing, and financing activities[9] - The company's cash and cash equivalents at the end of the period were CNY 322,003,336.23, down from CNY 713,057,275.43 at the end of Q1 2022[30] - The company's cash and cash equivalents decreased to ¥326,287,013.13 from ¥384,421,438.29 at the beginning of the year, a decline of 15.1%[21] - The total assets at the end of Q1 2023 were ¥6,029,891,650.30, a decrease of 1.25% from ¥6,106,273,672.25 at the end of the previous year[4] - The total liabilities decreased to ¥1,444,277,569.81 from ¥1,605,173,462.21, a reduction of 10%[22] Research and Development - Research and development expenses rose to ¥32,060,179.48, marking a 48.77% increase compared to ¥21,549,970.45 in the prior year, reflecting enhanced R&D efforts[9] - Research and development expenses increased to ¥32,060,179.48, representing a 48.8% rise from ¥21,549,970.45 in the previous year[24] - The company has established a mechanism for shared research and development resources with Shengwei Biological[17] Strategic Initiatives - The company invested CNY 63 million to acquire a 15% stake in Fujian Shengwei Biological Technology Co., Ltd., aiming to establish a comprehensive strategic partnership[17] - A strategic cooperation agreement and an asset leasing framework agreement were signed with Fujian Shengnong Development Co., Ltd. and Shengwei Biological, enhancing collaboration in healthy farming practices[18] - The company aims to expand its sales scale and brand influence through strategic partnerships and resource sharing[18] - The company is focused on innovation in product development and marketing strategies to enhance customer service[17] - The company is committed to strengthening its market position in poultry disease prevention[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,706[10] - The total number of restricted shares at the end of the period was 133,708,900 shares, with 11,242,492 shares released during the reporting period[14] - The top 10 unrestricted shareholders held a total of 144,951,392 shares, with the largest shareholder holding 41,868,620 shares[13] - The company reported no changes in the number of preferred shareholders during the period[12] Inventory and Expenses - The company reported a significant increase in inventory, which rose to ¥402,264,003.91 from ¥367,055,974.97, an increase of 9.5%[21] - Total operating costs for Q1 2023 were ¥361,812,573.71, up 15.4% from ¥313,567,270.68 in Q1 2022[24] - The company experienced a 140.15% increase in financial expenses, totaling ¥5,133,553.03, primarily due to reduced bank deposits and interest income[9]

编号：2023-002 | 投资者关系活动 | 特定对象调研 分析师会议 □媒体采访 业绩说明会  | | --- | --- | | 类别 | □新闻发布会 路演活动 | | | 现场参观 | | | 其他 | | 参与单位名称 | 线上参与公司 2022 年度网上业绩说明会的全体投资者 | | 时间 2023 | 年 04 月 14 日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） 董事长 李守军先生 | | 上市公司接待人 | | | | 独立董事 周睿女士 | | | 保荐代表人 郭玉良女士 | | 员姓名 | 董事会秘书 谢刚先生 | | | 财务负责人 李改变女士 | | | 1.请问公司猫三联疫苗研发进展，上市后的销售渠道布局规划 | | | 如何？ | | | 答:投资者您好！猫三联目前正在进行新兽药注册证书的申报， | | | 随着农业农村部加快审批政策的促进，公司猫三联疫苗有望早于原 | | | 有预期上市。从渠道端看，公司持续落实"三瑞齐发"的战略，通 | | | 过瑞派宠物医院旗下近600家宠物医院及中瑞供应链触达 ...

Group 1: Financial Performance - In 2022, the company achieved a revenue of 208,425.04 million CNY, representing a year-on-year growth of 3.84% [3] - The net profit attributable to the parent company was 34,669.87 million CNY, a decrease of 16.01% compared to the previous year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 28,071.54 million CNY, down by 1.37% year-on-year [3] Group 2: Production and Capacity Expansion - The company completed several capacity expansion projects, including the "New GMP Upgrade and Expansion Project" and "Natural Plant Industry Base," significantly increasing production capacity [3] - The new raw material drug factory of Longxiang Pharmaceutical began trial production in March 2022, with full capacity expected to be released in 2023 [6] Group 3: Research and Development - In 2022, the company obtained 8 new veterinary drug registration certificates and 35 patent technologies, achieving a record high in new veterinary drug registrations [3] - R&D investment increased by 11% in 2022, focusing on high-end talent recruitment and the "independent R&D + joint tackling" model [6] Group 4: Market Strategy and Product Development - The company plans to launch several new products in 2023, including vaccines for pigs and pets, enhancing its product matrix [7] - The pet segment revenue doubled in 2022, with a focus on expanding strategic cooperation with major clients in 2023 [4] Group 5: Strategic Partnerships - The company announced a strategic partnership with Shengnong Development and Shengwei Biological, aiming to enhance R&D capabilities and expand sales channels [5] - The collaboration will establish a poultry disease prevention research institute and a disease monitoring and early warning platform [5]

Financial Performance - The company reported a profit distribution plan to distribute a cash dividend of 3 RMB per 10 shares (including tax) based on a total of 468,018,786 shares[4]. - The company's operating revenue for 2022 was CNY 2,084,250,399, representing a 3.84% increase compared to CNY 2,007,138,304.57 in 2021[23]. - The net profit attributable to shareholders decreased by 16.01% to CNY 346,698,684.97 in 2022 from CNY 412,784,534.66 in 2021[23]. - The basic earnings per share fell by 27.00% to CNY 0.7488 in 2022, down from CNY 1.0258 in 2021[23]. - The total assets increased by 7.30% to CNY 6,106,273,672.25 at the end of 2022, compared to CNY 5,690,781,226.40 at the end of 2021[23]. - The net cash flow from operating activities was CNY 389,486,980.07, a 1.79% increase from CNY 382,628,909.13 in 2021[23]. - The company achieved a revenue of CNY 2,084.25 million in 2022, representing a year-on-year growth of 3.84%[71]. - The net profit attributable to the parent company was CNY 346.70 million, a decrease of 16.01% compared to the previous year[71]. - The total revenue for 2022 was CNY 2,084,250,399, representing a 3.84% increase from CNY 2,007,138,304.57 in 2021[89]. Market Position and Strategy - The company operates in the animal health sector, focusing on veterinary drugs and biological products for disease prevention and treatment[17]. - The company is positioned in the veterinary medicine manufacturing industry, providing disease prevention products and services for economic and companion animals[34]. - The company is recognized as one of the largest veterinary drug enterprises in China, with the most comprehensive product range and a focus on animal disease prevention solutions[40]. - The company has established strategic partnerships with top 300 poultry and top 200 livestock farming groups, enhancing market coverage and sales proportion[47]. - The company aims to cover 1,500 key poultry farming counties and 1,000 key livestock farming counties in China, focusing on small and medium-sized farms[49]. - The company has introduced a new pet product line, including dewormers and ear medications, and is strengthening its sales channels through strategic partnerships[50]. - The company has established multiple national and provincial innovation platforms, enhancing its research capabilities and fostering collaboration with over 30 renowned research institutions[61]. - The company is actively seeking overseas investment opportunities to implement its "going out" strategy and gradually expand its international market presence[149]. Research and Development - The company has developed 494 veterinary drug products, including 116 biological products and 198 chemical drug formulations, making it one of the largest enterprises in the domestic veterinary drug industry[65]. - The company has a strong focus on innovation, with 14 core technology platforms for drug research and development, including an AI drug development platform[71]. - The company has received 20 invention patents and 15 utility model patents during the reporting period, totaling 172 invention patents and 67 utility model patents by the end of the reporting period[74]. - The company achieved a research and development investment of ¥168,372,422.90 in 2022, representing an increase of 11.06% from ¥151,631,979.07 in 2021[106]. - The R&D investment accounted for 8.08% of the total operating revenue in 2022, up from 7.55% in 2021[106]. - The company has a total of 324 R&D personnel, including 20 PhDs and 199 master's degree holders, enhancing its research capabilities[75]. - The company has made significant breakthroughs in new product development, particularly in the fields of genetic engineering vaccines and multi-valent vaccines[71]. - The company is focusing on innovation and increasing R&D investment, which is expected to enhance its overall competitiveness in the industry[102]. Risks and Challenges - The company faces risks including animal epidemic risks, market competition risks, talent loss risks, and product development risks[4]. - The competitive landscape in the veterinary medicine industry is intensifying, prompting the company to optimize its industrial layout and enhance its comprehensive strength[151]. - The R&D cycle for veterinary products is long and uncertain, with risks associated with obtaining necessary approvals and market conditions[154]. - The company has implemented a strict credit management policy to mitigate risks associated with high accounts receivable, ensuring most customer debts remain within normal credit periods[156]. Governance and Management - The company emphasizes the importance of accurate financial reporting and has a dedicated team for financial oversight[4]. - The company has a clear ownership structure, with all intangible and tangible assets owned independently, ensuring no asset occupation by the controlling shareholder[175]. - The company has taken effective measures to protect the rights of minority shareholders during significant decision-making processes[162]. - The board of directors consists of 9 members, including 3 independent directors, enhancing decision-making capabilities and governance standards[164]. - The company has implemented a performance evaluation and incentive system for directors and senior management, promoting long-term development[171]. - The company has actively improved investor relations management, ensuring timely and accurate information disclosure to all shareholders[170]. - The company has established a dedicated investor hotline and email to address investor inquiries, enhancing communication transparency[170]. Future Outlook - The company’s future outlook includes potential market expansion and new product development in the veterinary sector[4]. - In 2023, the company plans to launch new products in the livestock sector, including inactivated vaccines for pig reproductive and respiratory syndrome and porcine circovirus, which will enhance product competitiveness[55]. - The poultry sector will introduce new products such as the LaSota+LDT3 bivalent live vaccine and inactivated vaccines, aiming to improve disease prevention solutions and expand channel coverage[55]. - The company plans to launch multiple new vaccines in 2023, including a trivalent inactivated vaccine for avian influenza and a gene-engineered vaccine for porcine circovirus type 2, contributing to high-quality development[142]. - The company is focusing on digital transformation, aiming to establish a digital manufacturing platform for veterinary drugs, integrating AI, information technology, and automation[146].